

Michael T Tetzlaff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1388900/publications.pdf>

Version: 2024-02-01

168
papers

15,409
citations

71004

43
h-index

23173

116
g-index

173
all docs

173
docs citations

173
times ranked

23714
citing authors

#	ARTICLE	IF	CITATIONS
1	Perianal condylomata lata mimicking carcinoma. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 209-214.	0.7	2
2	Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. <i>Annals of Diagnostic Pathology</i> , 2022, 59, 151967.	0.6	3
3	Cutaneous adnexal carcinosarcoma: Immunohistochemical and molecular evidence of epithelial mesenchymal transition. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 526-534.	0.7	1
4	Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 547-557.	0.7	3
5	Prognostic significance of acral lentiginous histologic type in T1 melanoma. <i>Modern Pathology</i> , 2021, 34, 572-583.	2.9	8
6	Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 674-679.	0.7	4
7	Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 377-383.	1.4	5
8	iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. <i>Frontiers in Oncology</i> , 2021, 11, 631766.	1.3	10
9	The tumor immune contexture of salivary duct carcinoma. <i>Head and Neck</i> , 2021, 43, 1213-1219.	0.9	10
10	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	7.7	32
11	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. <i>Scientific Reports</i> , 2021, 11, 9043.	1.6	13
12	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. <i>Nature Communications</i> , 2021, 12, 4031.	5.8	21
13	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
14	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1597-1605.	2.1	16
15	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. <i>Clinical Cancer Research</i> , 2021, 27, 5072-5083.	3.2	10
16	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa177.	0.4	12
17	Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, e9-e13.	0.4	11
18	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in BRAF-mutated melanoma. <i>Oncolmmunology</i> , 2021, 10, 1992880.	2.1	7

#	ARTICLE	IF	CITATIONS
19	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	6.0	369
20	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020, 33, 496-513.	2.9	19
21	Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 36-46.	0.7	2
22	Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma. <i>Modern Pathology</i> , 2020, 33, 42-55.	2.9	30
23	Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data?. <i>American Journal of Dermatopathology</i> , 2020, 42, 337-342.	0.3	9
24	Clinical validity of a gene expression signature in diagnostically uncertain neoplasms. <i>Personalized Medicine</i> , 2020, 17, 361-371.	0.8	11
25	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	1.3	11
26	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
27	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. <i>Immunotherapy</i> , 2020, 12, 1213-1219.	1.0	6
28	Without Missing a Beat: Absence of Cilia Informs the Diagnosis of Histopathologically Challenging Spitzoid Melanocytic Neoplasms. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1320-1323.	0.3	1
29	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155.		140
30	Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 954-959.	0.7	8
31	TERT amplification but not activation of canonical Wnt/ β -catenin pathway is involved in acral lentiginous melanoma progression to metastasis. <i>Modern Pathology</i> , 2020, 33, 2067-2074.	2.9	6
32	BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. <i>American Journal of Dermatopathology</i> , 2020, 42, 313-321.	0.3	10
33	BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue!. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 459-461.	0.7	1
34	Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma. <i>JAMA Ophthalmology</i> , 2020, 138, 374.	1.4	5
35	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
36	Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 490-493.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	0.8	23
38	Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis. <i>Modern Pathology</i> , 2020, 33, 1256-1263.	2.9	12
39	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2146-2156.e4.	0.3	14
40	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020, 11, 1839.	5.8	15
41	Multiplex Immunofluorescence Assays. <i>Methods in Molecular Biology</i> , 2020, 2055, 467-495.	0.4	44
42	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , 2020, 11, 600-618.	0.8	15
43	Spitzoid melanoma with histopathological features of <i>ALK</i> gene rearrangement exhibiting <i>ALK</i> copy number gain: a novel mechanism of <i>ALK</i> activation in spitzoid neoplasia. <i>British Journal of Dermatology</i> , 2019, 180, 404-408.	1.4	5
44	Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. <i>British Journal of Ophthalmology</i> , 2019, 103, 980-984.	2.1	46
45	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-like morphologic and molecular features. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 872-877.	0.7	4
46	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
47	The evolving landscape of HPV-related neoplasia in the head and neck. <i>Human Pathology</i> , 2019, 94, 29-39.	1.1	15
48	Unusual cutaneous metastatic carcinoma. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151399.	0.6	10
49	PARP Inhibition Suppresses GR β -MYCN β -CDK5 β -RB1 β -E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6839-6851.	3.2	50
50	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6429-6442.	3.2	61
51	Update on sebaceous neoplasia: the morphologic spectrum and molecular genetic drivers of carcinoma. <i>Diagnostic Histopathology</i> , 2019, 25, 102-109.	0.2	2
52	PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. , 2019, 60, 2388.		30
53	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. <i>Cancers</i> , 2019, 11, 754.	1.7	21
54	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1025-1035.	1.6	70

#	ARTICLE	IF	CITATIONS
55	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 860-865.	1.6	76
56	Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 ⁺ and CD16 ⁺ monocytes driving an innate immune response. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 627-636.	0.7	27
57	Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series. <i>American Journal of Dermatopathology</i> , 2019, 41, 167-179.	0.3	14
58	Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). <i>Journal of Neuro-Oncology</i> , 2019, 142, 499-509.	1.4	33
59	Validation Study of the <i>AJCC Cancer Staging Manual</i> , Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma. <i>JAMA Ophthalmology</i> , 2019, 137, 537.	1.4	27
60	B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. <i>Clinical Cancer Research</i> , 2019, 25, 3455-3467.	3.2	24
61	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019, 9, 628-645.	7.7	231
62	Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. <i>Cancers</i> , 2019, 11, 1714.	1.7	5
63	Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. <i>Cancers</i> , 2019, 11, 2031.	1.7	23
64	Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes. <i>American Journal of Surgical Pathology</i> , 2019, 43, 907-919.	2.1	2
65	Predictors of Local Recurrence for Eyelid Sebaceous Carcinoma: Questionable Value of Routine Conjunctival Map Biopsies for Detection of Pagetoid Spread. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, 419-425.	0.4	9
66	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 7585-7593.	3.2	17
67	Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 1280-1290.	3.2	39
68	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1692-1697.	3.3	237
69	Melanoma coexisting with solar elastosis: a potential pitfall in the differential diagnosis between nevus and melanoma. <i>Human Pathology</i> , 2019, 84, 270-274.	1.1	3
70	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 641-651.	3.2	21
71	Post-radiation vascular lesions of the breast. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 52-58.	0.7	17
72	Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. <i>Modern Pathology</i> , 2019, 32, 396-404.	2.9	41

#	ARTICLE	IF	CITATIONS
73	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052.	0.5	11
74	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 4703-4718.	0.8	6
75	Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 151-154.	0.6	3
76	Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 545-549.	0.7	5
77	Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 539-544.	0.7	13
78	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 504-507.	0.7	25
79	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 181-193.	5.1	233
80	Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 449-453.	0.6	2
81	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
82	Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma. <i>Human Pathology</i> , 2018, 77, 98-107.	1.1	8
83	Update on Merkel Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 31-43.	1.3	30
84	Immunohistochemical markers informing the diagnosis of sebaceous carcinoma and its distinction from its mimics: Adipophilin and factor XIIIa to the rescue?. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 29-32.	0.7	10
85	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	6.0	3,126
86	Differential expression of CCR4 in primary cutaneous gamma/delta (Î³Î´) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. <i>Journal of Dermatological Science</i> , 2018, 89, 88-91.	1.0	13
87	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , 2018, 2018, 1-19.	1.5	19
88	Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. <i>Journal of Cutaneous Pathology</i> , 2018, 46, 152-158.	0.7	5
89	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	15.2	521
90	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	15.2	592

#	ARTICLE	IF	CITATIONS
91	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	0.6	135
92	Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 764-773.	0.7	38
93	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1475874.	2.1	20
94	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 786-790.	0.7	18
95	Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs. <i>Cancer Research</i> , 2018, 78, 5349-5362.	0.4	36
96	Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. <i>Oncolmmunology</i> , 2018, 7, e1467856.	2.1	24
97	Cobomarsen, an oligonucleotide inhibitor of miR-155, coordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 428-444.	1.2	219
98	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105.	1.6	46
99	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	689
100	Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. <i>American Journal of Dermatopathology</i> , 2017, 39, 121-129.	0.3	96
101	Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. <i>Oncolmmunology</i> , 2017, 6, e1306618.	2.1	78
102	Clinicopathological features and clinical outcomes associated with TP53 and BRAF ^N mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017, 123, 1372-1381.	2.0	36
103	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	120
104	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2093-2104.	3.2	48
105	Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis. <i>JAMA Dermatology</i> , 2017, 153, 1302.	2.0	28
106	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1080-1086.	0.7	48
107	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607.	5.8	109
108	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1075-1079.	0.7	27

#	ARTICLE	IF	CITATIONS
109	Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 568-571.	0.6	1
110	Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 431-448.	0.7	29
111	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>Oncolmmunology</i> , 2017, 6, e1361097.	2.1	50
112	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>Oncolmmunology</i> , 2017, 6, e1321187.	2.1	45
113	Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 12-14.	0.9	11
114	Aberrant expression of β 1 in melanoma. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 790-793.	0.7	5
115	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176.	0.7	186
116	Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. <i>Human Pathology</i> , 2017, 59, 48-54.	1.1	8
117	TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform. <i>Frontiers in Medicine</i> , 2017, 4, 153.	1.2	16
118	Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma. <i>Oncotarget</i> , 2017, 8, 115140-115152.	0.8	9
119	A 60-year-old woman with an asymptomatic left lacrimal gland mass found incidentally. <i>Digital Journal of Ophthalmology: DJO</i> , 2017, 23, 118-120.	0.2	2
120	Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. <i>Journal of Pathology</i> , 2016, 240, 84-95.	2.1	63
121	Giemsa is the optimal counterstain for immunohistochemical detection of BRAF V600E mutation status in pigmented melanomas. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 722-724.	0.7	9
122	Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 688-696.	0.7	126
123	Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. <i>Modern Pathology</i> , 2016, 29, 832-843.	2.9	55
124	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016, 532, 250-254.	13.7	290
125	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	3.4	41
126	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5553-5563.	3.2	96

#	ARTICLE	IF	CITATIONS
127	A case report of Grover's disease from immunotherapy—a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50
128	Primary cutaneous CD30 ⁺ lymphoproliferative disorders. JDDG - Journal of the German Society of Dermatology, 2016, 14, 767-782.	0.4	12
129	Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a case. Journal of Cutaneous Pathology, 2016, 43, 1155-1160.	0.7	7
130	Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. Journal of Cutaneous Pathology, 2016, 43, 1161-1166.	0.7	40
131	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	2.3	106
132	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	7.7	785
133	Cutaneous metastasis from anaplastic thyroid carcinoma exhibiting exclusively a spindle cell morphology. A case report and review of literature. Journal of Cutaneous Pathology, 2016, 43, 252-257.	0.7	8
134	Histopathologic and mutational analysis of a case of blue nevus-like melanoma. Journal of Cutaneous Pathology, 2016, 43, 776-780.	0.7	17
135	BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Human Pathology, 2016, 50, 79-89.	1.1	18
136	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	7.7	1,158
137	Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors. Human Pathology, 2016, 53, 73-81.	1.1	11
138	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology, 2016, 5, e1136044.	2.1	55
139	Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. Journal of Clinical Pathology, 2016, 69, 382-390.	1.0	19
140	Epithelial, non-melanocytic and melanocytic proliferations of the ocular surface. Seminars in Diagnostic Pathology, 2016, 33, 122-132.	1.0	16
141	Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. Annals of Clinical and Laboratory Science, 2016, 46, 222-4.	0.2	5
142	Reed syndrome presenting with leiomyosarcoma. JAAD Case Reports, 2015, 1, 150-152.	0.4	16
143	Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Medicine, 2015, 4, 1440-1447.	1.3	44
144	Middle cerebral artery territory infarct due to Cryptococcus infection. Diagnostic Cytopathology, 2015, 43, 632-634.	0.5	6

#	ARTICLE	IF	CITATIONS
145	Use of clinical next-generation sequencing to identify melanomas harboring <i>SMARCB1</i> mutations. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 308-317.	0.7	11
146	Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. <i>Cancer</i> , 2015, 121, 1993-2003.	2.0	45
147	miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to <i>BRAF</i> inhibitor treatment. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 431-441.	1.5	41
148	HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. <i>Journal of Dermatological Science</i> , 2015, 77, 150-155.	1.0	11
149	Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. <i>Human Pathology</i> , 2015, 46, 558-569.	1.1	43
150	Distinct Pathways in the Pathogenesis of Sebaceous Carcinomas Implicated by Differentially Expressed MicroRNAs. <i>JAMA Ophthalmology</i> , 2015, 133, 1109.	1.4	33
151	Assessment of <i>BRAF</i> V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2887-2895.	1.9	38
152	Utility of <i>BRAF</i> V600E Immunohistochemistry Expression Pattern as a Surrogate of <i>BRAF</i> Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015, 46, 1101-1110.	1.1	43
153	Beyond <i>BRAF</i> V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.3	138
154	Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, E40-3.	0.6	4
155	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6582-6592.	3.2	493
156	Histological Features Associated With Vemurafenib-Induced Skin Toxicities. <i>American Journal of Dermatopathology</i> , 2014, 36, 557-561.	0.3	17
157	Detection of mitotic figures and <i>G2+</i> tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 846-852.	0.7	16
158	Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 5537-5546.	3.2	169
159	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. <i>International Journal of Dermatology</i> , 2014, 53, 376-384.	0.5	62
160	T-Cell Receptor- β in Gamma-Delta Phenotype Cutaneous T-Cell Lymphoma Can Be Accompanied by Atypical Expression of CD30, CD4, or TCR β F1 and an Indolent Clinical Course. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e195-e200.	0.2	14
161	Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. <i>Modern Pathology</i> , 2014, 27, 1468-1478.	2.9	54
162	Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with <i>BRAF</i> V600 Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 5527-5536.	3.2	145

#	ARTICLE	IF	CITATIONS
163	Primary orbital melanoma in association with cellular blue nevus. Digital Journal of Ophthalmology: DJO, 2014, 20, 35-40.	0.2	6
164	Granulomatous changes associated with pigmented purpuric dermatosis. Cutis, 2014, 94, 197-202.	0.4	7
165	Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Modern Pathology, 2013, 26, 1153-1160.	2.9	67
166	Ambiguous Melanocytic Tumors in a Tertiary Referral Center. American Journal of Surgical Pathology, 2013, 37, 1783-1796.	2.1	31
167	Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas. BioMed Research International, 2013, 2013, 1-7.	0.9	15
168	Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. Expert Review of Dermatology, 2011, 6, 355-357.	0.3	2